Combined lipid-lowering and antihypertensive therapy effects on hemostasis in metabolic sydrome patients
Abstract
The authors studied effects of short-term (8 weeks) combined lipid-lowering and antihypertensive therapy effects on hemostatic parameters in metabolic syndrome (MS) patients. The treatment with fibrates and antihypertensive medications was associated with fibrinogen level reduction (for combination of fenofibrate and atenolol). Statin therapy was associated with fibrinogen level decrease (lovastatin plus perindopril) and fibrinolysis activation (simvastatin plus indapamide). Possible pleiotropic mechanisms of lipid-lowering and antihypertensive medications could beneficially influence hemostasis system.
About the Authors
L. A. Ratnikova
ФГУ Государственный научноFисследовательский центр профилактической медицины Росздрава
Russian Federation
Russian Federation
V. A. Metelskaya
ФГУ Государственный научноFисследовательский центр профилактической медицины Росздрава
Russian Federation
Russian Federation
M. N. Mamedov
ФГУ Государственный научноFисследовательский центр профилактической медицины Росздрава
Russian Federation
Russian Federation
O. V. Kosmatova
ФГУ Государственный научноFисследовательский центр профилактической медицины Росздрава
Russian Federation
Russian Federation
N. V. Perova
ФГУ Государственный научноFисследовательский центр профилактической медицины Росздрава
Russian Federation
Russian Federation
References
1. Андреенко Г.В., Карабасова М.А., Лютова Л.В. и др. Методы исследования фибринолитической системы крови. М.: Изд-во МГУ, 1981. C. 40-42.
2. Васютина Е.И., Метельская В.А., Ахмеджанов Н.М. и др. Сравнительное изучение гиполипидемического эффекта и влияния на агрегацию тромбоцитов аторвастатина и симвастатина у больных сахарным диабетом 2 типа и комбинированной гиперлипидемией//Кардиология. 2003. Т. 43, № 1. С. 30-35.
3. Косматова О.В., Перова Н.В., Мамедов М.Н. и др. Эффективность сочетанной коррекции артериальной гипертонии и гиперлипидемии при метаболическом синдроме//Российский кардиологический журнал. 2001. № 6 (32). С. 38-43.
4. Ратникова Л.А., Метельская В.А., Мамедов М.Н. и др. Взаимосвязь между параметрами гемостаза и проявлениями метаболического синдрома у мужчин с мягкой и умеренной гипертонией//Терапевт. архив. 2000. № 9. С. 13-16.
5. Appel S.J., Harrell J.S., Davenport M.L. Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults. J. Am. Acad. Nurse. Pract. 2005; 17: 535-541.
6. Aso Y., Wakabayashi S., Yamamoto R., et al. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activa table fibrinolysis inhibitor. Diabetes Care. 2005; 28(9): 2211-2216.
7. Asplund-Carlson A., Hamsten A., Wiman B., et al. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDV triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo-and hypertriglyceridaemic men. Diabetologia 1993; 36: 817-825.
8. Beiraktari E.T., Tzallas, Tsimichodimos V.K., et al. Comparison of the efficacy of atorvastatin and micronised fenofibrate in the treatment of mixed hyperlipidemia. J. Cardiovasc. Risk 1999; 6: 113-116.
9. Bourcier T., Libby P. HMG-CoA-Reductase Inhibitors Reduce PAI-1 Expression by Human Vascular Smooth Muscle and Endothelial Cells. Atheroscler Thromb Vasc Biol 2000; 20: 556-568.
10. Chinetti-Ghauidi G., Fruchart J-C., Staels B. Therapeutical effects of PPAR agonists assessed by biomarker modulation. Biomarkers 2005; 10 Suppl 1: 30-36.
11. Davignon J. Advances in lipid-lowering therapy in atherosclerosis. Adv. Exp. Med. Biol. 2001; 498: 49-58.
12. Essig M., Nguyen G., Prie D., еt al. 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors increase Fibrinolytic Activity in Rat Aortic Endothelian Cells. Role of Geranylgeranylation and Rho Proteins. Circulation. Res. 1998; 83: 683-690.
13. Fogari R., Zoppi A. Is the effect of antihypertensive drugs on platelet aggregability and fibrinolysis clinically relevant? Am. J. Cardiovasc. Drugs 2005; 5: 211-223.
14. Gervois P., Vu-Dac N., Kleemann R., et al. Negative Regulation of Human Fibrinogen Gene Expression by Peroxisome Proliferator-activated Receptor a Agonists via Inhibition of CCAAT Box/Enhancer-binding Protein β. J. Biol. Chem. 2001; 276 (36): 33471-33477.
Review
For citations:
Ratnikova L.A., Metelskaya V.A., Mamedov M.N., Kosmatova O.V., Perova N.V. Combined lipid-lowering and antihypertensive therapy effects on hemostasis in metabolic sydrome patients. Russian Journal of Cardiology. 2006;(2):32-35. (In Russ.)
Views:
455
Email this article 